Literature DB >> 7858526

Distinct T cell populations distinguish chronic myeloid leukaemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions.

A R Datta1, A J Barrett, Y Z Jiang, A Guimarães, D A Mavroudis, F van Rhee, A A Gordon, A Madrigal.   

Abstract

Donor lymphocyte responses to minor histocompatibility antigen (mHA) differences are involved in allo-responses between HLA matched pairs causing GVHD and graft-versus-leukaemia (GVL). Since some mHA are tissue-restricted, GVHD and GVL responses may be separable. We studied donor lymphocyte responses to patients with CML in a series of 10 HLA-matched sibling and 10 unrelated donor-recipient pairs comparing proliferation to recipient PHA blasts and CML cells and attempting to selectively deplete responses to PHA blasts in vitro. Responses in counts per min (c.p.m) to CML cells and PHA blasts were, respectively, 2809 +/- 2205 (SD) and 7376 +/- 1877 in related and 12,107 +/- 7191 and 26,136 +/- 22,479 in unrelated pairs. Autologous responses to PHA blasts were significantly lower (mean 779 +/- 735) (p < 0.001). Results correlated with clinical outcome: higher responses to recipient cells correlated with transplant-related death (p = 0.02 for CML and p = 0.06 for PHA blasts). Higher responses to CML correlated with GVHD grade > or = II (p = 0.025). Donor lymphocytes exposed to recipient PHA blasts for 5 days and treated with a ricin-conjugated anti-CD25 antibody retained over 75% of their response to CML but < 10% to PHA blasts. Similarly, depletion of response to CML but not to PHA blasts occurred when CML was the primary challenge. These results indicate that distinct populations of donor T cells respond to recipient leukaemic and non-leukaemic cells, and provide the basis for a clinically applicable technique to selectively deplete donor GVHD reacting cells while conserving GVL.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7858526

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  7 in total

1.  The clinical implications of mixed lymphocyte reaction with leukemic cells.

Authors:  Hee-Je Kim; Tai-Gyu Kim; Hyun Il Cho; Hoon Han; Woo-Sung Min; Chun-Choo Kim
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

2.  Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation.

Authors:  Scott R Solomon; Stephan Mielke; Bipin N Savani; Aldemar Montero; Laura Wisch; Richard Childs; Nancy Hensel; John Schindler; Victor Ghetie; Susan F Leitman; Thao Mai; Charles S Carter; Roger Kurlander; Elizabeth J Read; Ellen S Vitetta; A John Barrett
Journal:  Blood       Date:  2005-04-07       Impact factor: 22.113

Review 3.  Immunotherapy of AML: future directions.

Authors:  M W Lowdell; M B Koh
Journal:  J Clin Pathol       Date:  2000-01       Impact factor: 3.411

4.  Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand.

Authors:  Osnat Bohana-Kashtan; Sebastien Morisot; Richard Hildreth; Cory Brayton; Hyam I Levitsky; Curt I Civin
Journal:  J Immunol       Date:  2009-06-17       Impact factor: 5.422

Review 5.  Graft-versus-leukemia and graft-versus-lymphoma effects of allogeneic bone marrow transplantation and of allogeneic donor leukocyte transfusions.

Authors:  P Vandenberghe; M A Boogaerts
Journal:  Ann Hematol       Date:  1995-11       Impact factor: 3.673

6.  A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique.

Authors:  Stephan Mielke; Raquel Nunes; Katayoun Rezvani; Vicki S Fellowes; Annie Venne; Scott R Solomon; Yong Fan; Emma Gostick; David A Price; Christian Scotto; Elizabeth J Read; A John Barrett
Journal:  Blood       Date:  2007-09-18       Impact factor: 22.113

Review 7.  Microchimerism and scleroderma: an update.

Authors:  Carol M Artlett
Journal:  Curr Rheumatol Rep       Date:  2003-04       Impact factor: 4.686

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.